|                | Events/total (%) | Better (n=296) | Worse (n=296) | HR (95% CI) | P-value | Interaction |
|----------------|------------------|----------------|---------------|-------------|---------|-------------|
| **Age (yr)**   |                  |                |               |             |         |             |
| <70            | 51 / 239 (21.3)  | 0.944 (0.717–1.243) | 0.682         | 0.010       |         |             |
| ≥70            | 18 / 57 (31.6)   | 2.399 (1.205–4.773) |              |             |         |             |
| **Sex**        |                  |                |               |             |         |             |
| Male           | 35 / 157 (22.3)  | 1.315 (0.889–1.943) | 0.170         | 0.286       |         |             |
| Female         | 34 / 139 (24.5)  | 0.978 (0.696–1.373) |              |             |         |             |
| **DM**         |                  |                |               |             |         |             |
| No             | 35 / 161 (21.7)  | 1.126 (0.810–1.566) | 0.481         | 0.812       |         |             |
| Yes            | 34 / 135 (25.2)  | 1.055 (0.707–1.574) |              |             |         |             |
| **HTN**        |                  |                |               |             |         |             |
| No             | 3 / 40 (7.5)     | 1.287 (0.397–4.169) | 0.674         | 0.698       |         |             |
| Yes            | 66 / 256 (25.8)  | 1.036 (0.794–1.353) |              |             |         |             |
| **Previous CVD**|                |                |               |             |         |             |
| No             | 30 / 138 (21.7)  | 1.114 (0.768–1.615) | 0.569         | 0.980       |         |             |
| Yes            | 39 / 158 (24.7)  | 1.088 (0.771–1.537) |              |             |         |             |
| **Previous HF**|                |                |               |             |         |             |
| No             | 48 / 190 (25.3)  | 1.122 (0.832–1.513) | 0.449         | 0.841       |         |             |
| Yes            | 21 / 106 (19.8)  | 1.042 (0.658–1.649) |              |             |         |             |
| **Hb < 10 g/dL**|                |                |               |             |         |             |
| No             | 55 / 217 (25.3)  | 1.156 (0.867–1.541) | 0.324         | 0.571       |         |             |
| Yes            | 14 / 79 (17.7)   | 0.969 (0.565–1.662) |              |             |         |             |
| **Albumin < 3.5 g/dL** | | | | | | |
| No             | 63 / 272 (23.2)  | 1.107 (0.847–1.448) | 0.457         | 0.607       |         |             |
| Yes            | 6 / 24 (25.0)    | 0.865 (0.387–1.933) |              |             |         |             |
| **RAS blockers**|                |                |               |             |         |             |
| No             | 33 / 153 (21.6)  | 1.264 (0.867–1.843) | 0.224         | 0.329       |         |             |
| Yes            | 36 / 143 (25.2)  | 0.978 (0.693–1.382) |              |             |         |             |
| **β-blockers** |                |                |               |             |         |             |
| No             | 30 / 176 (17.0)  | 1.429 (0.968–2.111) | 0.073         | 0.041       |         |             |
| Yes            | 39 / 120 (32.5)  | 0.827 (0.582–1.175) |              |             |         |             |

**Supplementary Figure 1.** Association of log sST2 and cardiovascular disease in subgroups of patients (per SD increase). CI, confidence interval; CVD, cardiovascular disease; DM, diabetes mellitus; Hb, hemoglobin; HF, heart failure; HR, hazard ratio; HTN, hypertension; RAS, renin-angiotensin system; SD, standard deviation; sST2, soluble suppression of tumorigenicity-2.